^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Chronic Myeloid Leukemia
    Drug:Synribo (omacetaxine mepesuccinate) (Apoptosis stimulant, MCL1 inhibitor, MYC inhibitor, Protein synthesis inhibitor, G1-S-specific cyclin-D1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    11/26/2019
    Excerpt:
    SYNRIBO for Injection is indicated for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI).
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    08/28/2020
    Excerpt:
    Chronic Myeloid Leukemia: Useful in certain circumstances...Omacetaxine